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Endovascular therapy for acute limb ischemia
Vikram S. Kashyap, MD,a Ramyar Gilani, MD,a James F. Bena, MS,b Mohsen Bannazadeh, MD,a and
Timur P. Sarac, MD,a Cleveland, Ohio
Background:Acute limb ischemia (ALI) of the lower extremities remains a challenging clinical dilemma. Treatment of ALI
has shifted toward endovascular therapies. The purpose of this study was to assess outcomes in patients treated for ALI
with intra-arterial thrombolysis and/or adjuvant endovascular techniques.
Methods: Consecutive patients with ALI of the lower extremities treated via endovascular intra-arterial methods between
January 1, 2005 and September 30, 2007 were identified and reviewed. Comparisons of success, thrombolysis days, and
all 30-day outcomes except mortality were performed using generalized estimating equations with logistic and propor-
tional odds regression. Thirty-day mortality was assessed using logistic regression. Long-term patency, limb salvage, and
survival were assessed using time-to-event methods, including Kaplan-Meier estimation and Cox proportional hazards
models.
Results: The analyzed dataset included 129 limbs treated in 119 patients presenting with ALI (class I 68%, class IIa 23%,
class IIb 9%). The mean follow-up was 16.8 months (range: 0-43 months). Technical success was achieved in 82% cases.
The 30-day mortality rate was 6.0% with all 30-day deaths occurring in females (P .002). One (0.76%) central nervous
system hemorrhage (CNS) was noted in this cohort. Primary patency for the entire cohort at 12 and 24months was 50.1%
(95% confidence interval [CI], 39.5-60.7) and 37.7% (95% CI, 26.2-49.1), respectively, while secondary patency was
74.0% (95% CI, 64.9-83.1) and 65.3% (95% CI, 54.5-76.2). Multivariable analyses identified patients presenting with
femoropopliteal (hazard ratio [HR] 2.63) or tibial thrombosis (HR 2.80); graft thrombosis (vs native artery thrombosis,
HR 2.57) and long-term dialysis (HR 3.66, 95% CI, 2.35-5.71, P < .001) were associated with poorer primary patency
rates. Cumulative limb salvage at 24months was 68.8% (95%CI: 59.5-78.1) with female gender (HR 3.34, P .002) and
thrombolysis>3 days (HR 2.35, P .019) associated with an increased risk of limb loss. Overall 36-month survival was
84.5% (95% CI: 77.5-91.6). Women had decreased survival rates both in the short- and midterm (HR 6.29; 95% CI,
1.78-22.28; P  .004).
Conclusions: Endovascular therapy with thrombolysis remains an effective treatment option for patients presenting with
lower extremity ALI. Thrombolysis should be limited to <3 days. Female gender negatively affects the rates of limb
salvage and survival. ( J Vasc Surg 2011;53:340-6.)
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lPatients with peripheral arterial disease (PAD) of the
lower extremities often suffer from chronic conditions in-
cluding claudication, rest pain, or ulceration. A small subset
of patients may suffer from acute limb ischemia (ALI),
which can lead to loss of limb and life without prompt
treatment.1 This devastating condition requires prompt
identification of the acute arterial occlusion in the leg and
effective treatment. It remains a challenging scenario for
clinicians. In addition to the limb ischemia, the systemic
sequalae from ischemia can lead to high morbidity and
mortality rates.1
After therapeutic anticoagulation is achieved, tradition-
ally, urgent surgical intervention follows employing throm-
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340oembolectomy, placement of a bypass graft, or other
echniques to restore arterial flow to the extremity. Early
perative intervention, however, is associated with a signif-
cant risk of perioperative mortality. Mortality rates in ex-
ess of 25% following open surgical repair for ALI were
eported in the late 1970s.2 Jivegard and colleagues cor-
oborated these findings a decade later, documenting a 20%
ortality rate in patients undergoing operative revascular-
zation for acute limb ischemia.3 In spite of advances in
urgical technique and perioperative care, the current risk
f morbidity and mortality following open surgical inter-
ention continues to be significant. The mortality rate of
urgical revascularization performed in the setting of ALI
emains high, mostly because many patients poorly tolerate
n extensive procedure performed without adequate pre-
perative preparation.4,5 Cardiopulmonary complications
ccur with frequency, accounting for an unacceptably high
ortality rate over midterm follow-up. Individuals who
resent with ALI comprise one of the sickest subgroups of
atients that the vascular specialist is asked to treat.6 Fur-
hermore, operative strategies are often suboptimal. Resid-
al thrombus has been demonstrated in a large fraction of
essels after open surgical thrombectomies.7,8
The development of effective medications to dissolve
ccluding thrombus led to the increasing use of thrombo-
ytic therapy in patients with ALI. Randomized control
rials have provided a rationale for thrombolysis as a first
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Volume 53, Number 2 Kashyap et al 341step in patients with ALI vs immediate operative revascu-
larization.4,9,10 Catheter directed thrombolysis offers sev-
eral potential advantages to lessen the pitfalls of open
techniques. By utilizing an endovascular approach and local
anesthesia, the risks of general anesthesia are minimized
within a subgroup of patients that are at their physiologic
limits. In addition, enzymatic dissolution of thrombus al-
lows for more effective clot resolution particularly within
distal arterial beds that are often resistant to open throm-
bectomy. Successful clot dissolution will unveil a “culprit”
lesion responsible for initiating thrombosis. Experience has
shown that patency rates are markedly dependent on the
discovery and treatment of such underlying lesions.11
We have pursued an aggressive approach to limb sal-
vage in patients with ALI and preferentially use endovascu-
lar therapy in these patients with thrombolysis and/or
percutaneous mechanical thrombectomy (PMT) devices.
The advent of PMT has allowed removing clot burden
quickly and restoring flow to the foot during the initial
angiogram. The purpose of this study was to review our
contemporary experience treating ALI via endovascular
therapy. The specific goals of the study were to assess
periprocedural safety, technical outcome, procedural dura-
bility, and survival of this group of patients.
PATIENTS AND METHODS
Patient population. After Institutional Review Board
(IRB) approval, a retrospective review was performed of
patients at the Cleveland Clinic Foundation (CCF) from
January 1, 2005 to September 30, 2007 who presented
with ALI. A prospectively collected registry was queried
using current procedural terminology (CPT) codes to iden-
tify all patients treated with endovascular techniques for
ALI of the lower extremities. In this two and a half year
interval, we identified 129 limbs in 119 patients that were
consecutively treated for lower extremity ALI at our insti-
tution. During this time frame, approximately 20 patients
underwent surgical therapy for ALI due to surgeon prefer-
ence. All clinical, perioperative, and demographic data were
obtained through review of the hospital and physician
electronic records. The original angiographic imaging was
reviewed via captured and stored electronic images (Magic-
View; Siemens Medical Systems, Malvern, Pa). Preopera-
tive data were obtained including demographics, athero-
sclerotic risk factors, symptoms, and other clinical variables.
ALI was defined as the sudden onset or worsening of
ischemic manifestations within the lower extremities due to
arterial thrombosis or embolism. The involved segment
was further classified as native vessel or graft, the latter
including both autogenous and prosthetic conduits. Previ-
ous endovascular therapy or open surgery on the affected
ischemic side was recorded. Rutherford’s classification of
ALI was determined based on the physician initial evalua-
tion that adhered to the published criteria.12
Operative technique. Endovascular procedures were
performed by the faculty of the Cleveland Clinic Depart-
ment of Vascular Surgery. Procedural technical details for
all included limbs (N  129) were recorded. During this time period, recombinant tissue plasminogen activator (rt-
A, Activase; Genentech, Inc, San Francisco, Calif) was
sed universally for thrombolysis at a dose of 0.5-1.0
g/h. Adjuvant procedures were often needed (91%) and
ncluded both endovascular and open techniques to treat
he “culprit lesion” after thrombolytic dissolution of the
hrombus. These included endarterectomy, open bypass
evision, angioplasty, and stenting. PMT was evaluated as
n individual entity and included power-pulse tech-
iques.13 The AngioJet devices (Possis, Medical Inc, Min-
eapolis, Minn) were preferentially used for PMT. Throm-
olysis days were based on the total number of days a
atient underwent thrombolysis. Technical success was de-
endent on the re-establishment of in-line blood flow to
he foot. The requirement of a new surgical bypass consti-
uted a technical failure.
Data analysis and follow-up. Periprocedure data, as-
ociated morbidity, and mortality within 30 days of the
rocedure were determined. Long-term follow-up docu-
entation of patency included the presence of palpable
emoral/distal artery pulses, resolution of symptoms,
nd/or noninvasive vascular laboratory testing. The last
ncluded ankle-brachial indices (ABI), pulse-volume re-
ordings (PVR), and color-flow Doppler ultrasound. We
re able to obtain reliable follow-up data for the vast
ajority of patients with noninvasive vascular laboratory
esting in 101/129 limbs (78%). The average length of
ollow-up was 16.8 months (range 0-43 months).
Primary and secondary patency and limb salvage were
etermined in concordance with the Society for Vascular
urgery guidelines.12 Primary end points evaluated at a
imb level (N  129) were primary patency, secondary
atency, and limb salvage while survival was evaluated at a
atient level (n 119). Primary patency was defined as the
bility to maintain uninterrupted patency of the reference
imb vasculature. Secondary patency was defined as the
e-establishment of flow in the setting of re-thrombosis.
imb salvage was defined as freedom from major amputa-
ion above the foot level. The majority of patients had
bjective noninvasive vascular laboratory testing at fol-
ow-up visits planned for every 6 months. Loss of patency
as determined by a drop in ABI greater than 0.15, and/or
oppler ultrasound findings of occlusion in the treated
egment. Failures underwent repeat angiography. In a
mall fraction of patients, the loss of previously palpable
ulses and/or recurrent symptoms, prompted angiogra-
hy. Mortality was verified using the Social Security Death
ndex database.
Statistical methods. Summaries of the categorical fac-
ors were described using frequencies and percentages. The
ean and standard deviation were used to summarize
ontinuous measure distributions. Comparisons of success,
hrombolysis days, and all 30-day outcomes except mortal-
ty were performed using generalized estimating equations
ith logistic and proportional odds regression. Thirty-day
ortality was assessed using logistic regression. Long-term
atency, limb salvage, and survival were assessed using
ime-to-event methods, including Kaplan-Meier estima-
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February 2011342 Kashyap et altion and Cox proportional hazards models. Marginal mod-
els were used where appropriate to adjust for multiple limbs
per patient, where appropriate. Tests assumed a significance
level of 0.05. Analyses were performed using SAS (version
9.1; Cary, NC) and initial plots were created using R
software (version 2.4; Vienna, Austria).
RESULTS
Patients presenting with ALI of the lower extremities
had significant comorbidities along with a long history of
peripheral arterial disease. During the study interval, 119
patients underwent thrombolysis for ALI. Ten patients had
either both limbs or different arterial regions affected by
ALI. These patients had a mean age of 64 years (Table I),
were the majority male (59%), and carried the atheroscle-
rotic risk factors of hypertension (71%), diabetes (24%),
hyperlipidemia (50%), and smoking (69%). This cohort had
severe pre-existing PAD. One hundred and six of the 129
limbs affected by ALI (82%) had either prior surgical revas-
cularization or prior endovascular therapy in the ipsilateral
extremity (Table II). Graft thrombosis predominated (93,
72%). Upon presentation, the majority of limbs were cate-
gorized as Rutherford class I (88, 68%) or class IIa (30,
23%) ischemia. However, 10 limbs fell under the category
of Rutherford class IIb and 1 limb was class III. These 11
limbs were combined for statistical purposes. The involved
segment was distributed among the segments of the lower
limb arterial tree with the femoropopliteal location being
most affected and a subgroup of limbs (20, 16%) having
multilevel thrombosis.
Procedural details from the interventions performed
are summarized in Table III. From a technical standpoint,
cases were mostly done from a contralateral femoral ap-
proach (60%). PMT was utilized in nearly half the cases
(47%) in addition to thrombolysis. This included PMT to
reduce thrombus burden at the beginning of the thrombol-
ysis and during thrombolytic check angiograms, as well as,
PMTutilized to lace the thrombus with thrombolytic agent
(“power-pulse technique”).14 There were no PMT-related
Table I. Patient baseline characteristics (n119)
Patient variables n (%)
Male 70 (59)
Hypertension 84 (71)
Diabetes 28 (24)
Hyperlipidemia 60 (50)
Smokinga 82 (69)
CAD 66 (55)
Arrhythmia 11 (9)
COPD 14 (12)
Dialysis dependent 5 (4)
Mean (SD)
Age (year) 63.7 (14.4)
Creatinine (mg/dL) 1.0 (0.4)
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary
disease.
aWithin 10 years.complications including hemolysis. The total number of whrombolysis days was divided into three subgroups: most
imbs underwent 0-1 days (63, 49%) or 1-2 days (50, 39%),
hile a few limbs required 3 or more days (16, 12%). In an
verwhelming majority of cases (91%), an adjuvant proce-
ure was performed to treat the “culprit lesion” leading to
hrombosis. This was a purely percutaneous endovascular
rocedure in 56%, an open surgical procedure in 15% and a
ombined approach in 28%. Technical success was achieved
n 106 (82%) of treated limbs. Univariable analyses found
hat the location of the thrombus was associated with
echnical success. Femoropopliteal thrombosis (odds ratio
OR] 0.27) and tibial thrombosis (OR 0.10) fared poorly
ompared with thrombosis in the aortoiliac location (P 
02). In the remaining patients not characterized as a
echnical success (n  23), surgical revascularization was
uccessful (n  5) or medical therapy (ie, anticoagulation,
 3) sufficed in preventing limb loss. Early amputation
as needed in 11 limbs, and an additional four patients died
fter technically unsuccessful cases.
The early (30-day) outcomes indicate that overall, 82%
f patients were alive and had their limb intact after endo-
ascular treatment for ALI. However, this was associated
able II. Limb baseline characteristics (N  129)
imb variables Percentage, N (%)
utherford class
I 88 (68)
IIa 30 (23)
IIba 11 (9)
hrombosis vessel
Native artery 36 (28)
Graft 93 (72)
hrombosis location
Aortoiliac (AI) 29 (22)
Femoropopliteal (FP) 51 (40)
Tibial (T) 29 (22)
Multilevel 20 (16)
revious ipsilateral revascularization
Endovascular therapy 54 (42)
Either open revascularization or
endovascular therapy
106 (82)
One limb was Rutherford class III.
able III. Procedural details (N  129)
echnical variable N (%)
ontralateral access 77 (60)
MT 60 (47)
hrombolysis days
0-1 63 (49)
1-2 50 (39)
3 16 (12)
djuvant procedure 118 (91)
Endovascular 69 (54)
Open 17 (13)
Combined 32 (25)
echnical success 106 (82)
MT, Percutaneous mechanical thrombectomy.ith a risk for procedure-related complications. Access site
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Volume 53, Number 2 Kashyap et al 343hematoma (11%), bleeding requiring transfusion (8%), and
compartment syndrome (4%) occurred after ischemia-
thrombolysis-reperfusion. A single patient (0.76%) developed
intracranial bleeding.Mortality was observed in seven patients
(6%), four occurring after amputation. All of the early mortal-
ities occurred in female patients (P  .002). In addition to
gender, technical failure was predictive of mortality (OR,
5.88; 95% confidence interval [CI], 1.23-33.3; P .03).
Twenty limbs required early amputation (15.5%); 11
after unsuccessful thrombolytic cases, as outlined above.
On univariable analysis, factors associated with early ampu-
tation are displayed in Table IV. These included female
gender (OR, 2.91; 95% CI, 1.06-7.97; P .038) and three
ormore thrombolysis days (OR, 9.38; 95%CI, 2.06-42.83;
P .004). Technical failure was also associated with 30-day
amputation (OR, 8.33; 95% CI, 2.86-25.0; P  .001).
Furthermore, an adjuvant procedure treating the “culprit
lesion” was predictive of improved outcomes and decreased
Table IV. Univariable summaries of the associations with
Factor Level Amputati
Female No 9.7
Yes 24.1
Hypertension No 18.9
Yes 14.6
Diabetes No 17.4
Yes 10.7
Dialysis No 15.7
Yes 20
Hyperlipidemia No 21
Yes 10.9
Arrhythmia No 17.5
Yes 0
COPD No 17.9
Yes 0
Smoking No 18.9
Yes 14.6
Graft thrombosis No 14.3
Yes 16.5
Previous endovascular therapy No 20.8
Yes 9.3
Rutherford class 1 14
2a 13.3
2b 40
Location Al 6.9
FP 10.2
T 24.1
Multilevel 31.6
Adjuvant procedure No 45.5
Yes 13
PMT None 14.7
PMT 21.1
PMT/PowerPulse 10
Thrombolysis days 0-1 9.7
1-2 16.3
3 40
Age 10 year increase
Creatinine (nondialysis) Per unit increase
AI, Aortoiliac; CI, confidence interval; COPD, chronic obstructive pulm
mechanical thrombectomy; T, Tibial, which does not adjust for correlation wi
P values are from Wald tests of the odds ratio.risk of amputation at 30 days (OR, 0.17; 95% CI, 0.04- t.62; P  .008). There was a trend for tibial thrombosis
OR 4.34) or multilevel thrombosis (OR 7.03) to increase
ig 1. Kaplan-Meier estimates of primary patency, secondary pa-
ency, and limb salvage for the entire cohort are shown. Standard
rror 10% for all of the curves displayed.
ay amputation are shown
Odds ratio (95% CI) P value vs reference P value overall
1.00 .038
2.91 (1.06, 7.97) .038
1.00 .76
0.84 (0.27, 2.60) .76
1.00 .37
0.51 (0.11, 2.23) .37
1.00 .77
1.39 (0.15, 13.20) .77
1.00 .15
0.49 (0.18, 1.30) .15
1.00 .21F
NA .21F
1.00 .12F
NA .12F
1.00 .31
0.57 (0.19, 1.68) .31
1.00 .73
1.21 (0.40, 3.64) .73
1.00 .36
0.28 (0.00, 1502.4) .77
1.00 .55
0.89 (0.30, 2.65) .84
2.71 (0.38, 19.36) .32
1.00 .071
1.70 (0.28, 10.40) .57
4.34 (0.70, 26.83) .11
7.03 (1.13, 43.55) .036
1.00 .008
0.17 (0.04, 0.62) .008
1.00 .31
2.16 (0.65, 7.20) .21
0.74 (0.04, 12.92) .84
1.00 .012
2.25 (0.58, 8.74) .24
9.38 (2.06, 42.83) .004
0.81 (0.55, 1.19) .29
0.19 (0.03, 1.38) .10
disease; F, Fisher exact test; FP, Femoropopliteal; PMT, percutaneous
tient was used, due to non-convergence of the GEE logistic regression model.30-d
on %
onaryhe risk of amputation.
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were assessed using time-to-event methods (Fig 1). Pri-
mary patency for the entire cohort at 12 and 24months was
50.1% (95% CI, 39.5-60.7) and 37.7% (95% CI, 26.2-
49.1), respectively. Secondary patency at 12 and 24months
was 74.0% (95% CI, 64.9-83.1) and 65.3% (95% CI, 54.5-
76.2), respectively. A multivariable model for primary pa-
tency loss was constructed (Table V, A). Patients present-
ing with femoropopliteal (hazard ratio [HR] 2.63) or tibial
thrombosis (HR 2.80), and graft thrombosis (vs native
artery thrombosis, HR 2.57, Fig 2) were associated with
poorer primary patency rates. Primary patency at 12
months was not achieved in each of the five patients requir-
ing long-term dialysis (HR 3.66, 95% CI, 2.35- 5.71, P 
.001).
Limb salvage at 12 months was 74.6% (95% CI, 66.5-
82.7) and at 24 months was 68.8% (95% CI: 59.5-78.1).
Multivariable modeling (Table V, B) revealed that female
gender (HR 3.34, P  .002) and thrombolysis 3 days
(HR 2.35, P .019) were associated with an increased risk
of limb loss. As expected, initial technical success (HR
0.32) and performance of an adjuvant procedure (HR
0.30) were associated with lower rates of amputation long-
term.
Survival of the entire cohort at 12 months was 85.7%
(95% CI, 79.0- 92.5) and at 24 months and 36 months was
84.5% (95% CI: 77.5-91.6, Fig 3). Female patients were
Table V, A. The multivariable model for primary patency
Measure Level Hazard rati
Dialysis Yes 3.66 (2.3
Graft thrombus Yes 2.57 (1.2
Locationa Fempop 2.63 (1.1
Tibial 2.80 (1.0
Multilevel 1.03 (0.3
Technical success Yes 0.25 (0.1
P values are from the Cox proportional hazards model.
CI, Confidence interval.
aCompared to aortoiliac location.
Fig 2. Kaplan-Meier estimates of primary patency comparing
graft vs native artery thrombolysis. Standard error 10% for all of
the curves displayed.found to have decreased survival rates both related to early fostprocedure deaths and during the first year in follow-up
HR 6.29; 95% CI, 1.78-22.28; P  .004). Chronic ob-
tructive pulmonary disease (COPD) (HR 3.18) and each
0-year increase in age (HR 1.71) were the other variables
ound to be associated with decreased survival on multiva-
iable modeling (Table V, C).
ISCUSSION
ALI of the lower extremities remains a challenging
ntity for clinicians with significant limb loss and mortality.
rospective randomized trials have shown that a thrombol-
sis-first strategy allows for rates of limb salvage and survival
hat rival open surgical revascularization.4,9,10 Further-
ore, advances in endovascular techniques have made the
ercutaneous treatment of underlying “culprit” lesions;
hus, allowing the treatment of ALI with just an arterial
uncture.
Our study re-confirms that thrombolysis can be per-
ormed relatively safely from the perspective of complica-
ions and with robust technical success. Our results indicate
hat a vast majority of patients (82%) treated with endovas-
ular therapy can survive an episode of ALI with their limbs
ntact. In over 90% of cases, dissolution of the thrombotic
cclusion with thrombolytic therapy uncovered a lesion
hat could be treated via either endovascular methods or
ith a limited surgical operation. Thrombolysis did not
ead to a high rate of bleeding complications as often
eared. Transfusion requirement (8.5%) and intracranial
leeding (0.76%) rates were low and compared favorably
ith results from open surgical revascularization for
LI.
3, 9, 15
However, these results paint a sobering picture for
ome patients presenting with ALI. Survival in the near-
ndmidterm was worse for females. This was skewed by the
act that all 30-day mortalities occurred in women. Addi-
ionally, review of the survival curves showed continued
ortality in the first year after ALI for women, but not so
or men.Whether the inflammatory milieu is more severe in
emales or that females with ALI represent a more virulent
orm of atherothrombosis remains unknown. Regardless,
hese results point to increased caution for thrombolysis in
emale patients. The 30-day amputation rate was 15.9%,
hich is not negligible but similar to other reports on
LI.
14, 16-18
Correlated with increased early amputation was
is summarized
CI) P value vs reference P value overall
1) .001 .001
3) .012 .012
2) .025 .024
1) .033
0) .95
6) .001 .001loss
o (95%
5, 5.7
4, 5.3
3, 6.1
9, 7.2
8, 2.8
1, 0.5emale gender. Given anatomic differences in vessel size,
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Volume 53, Number 2 Kashyap et al 345female patients may tolerate less thrombus burden and
therefore have poorer results with thrombolysis. In addi-
tion, 3 or more days of thrombolysis were associated with
amputation. We suspect that this is due to greater throm-
bus burden and/or thrombus resistance to thrombolysis.
Patients requiring three or more days of thrombolysis may
have components of chronic thrombosis (despite their
acute presentation) that is resistant to fibrinolytic therapy.
Thus, these patients will not have complete dissolution of
the thrombotic material but accrue increasing risk with
persistent thrombolytic infusion.11,19 This finding has led
to a change in our practice of limiting arterial thrombolysis
to3 days. An aggressive posture for the treatment of ALI
remains warranted, but thrombolysis should be stopped if
patency is not restored in 3 days. Lastly, graft thrombosis
treated with thrombolysis fared worse in regard to patency
Table V, B. The multivariable model for limb loss is summ
Measure Level Hazard rati
Gender Female 3.34 (1.5
Adjuvant procedure Yes 0.30 (0.1
Thrombolysis daysa 1-2 0.83 (0.3
3 2.35 (1.1
Technical success Yes 0.32 (0.1
P values are from the Cox proportional hazards model.
CI, Confidence interval.
aCompared to 1 day.
Fig 3. Kaplan-Meier estimates of survival for the entire cohort
and by gender. Standard error10% for all of the curves displayed.
Table V, C. The multivariable model for long-term
survival is summarized
Measure Level
Hazard ratio
(95% CI)
P value vs
reference
P value
overall
Gender Female 6.29 (1.78, 22.28) .004 .004
COPD Yes 3.18 (1.08, 9.31) .035 .035
Age 10-year
increase
1.71 (1.09, 2.69) .021 .021
CI, Confidence interval; COPD, chronic obstructive pulmonary disease.
P values are from the Cox proportional hazards model.thannative artery thrombosis. Althoughnot directly evaluated Tiven the small numbers, this may be explained by polytetra-
uoroethylene (PTFE) bypasses in the femoropopliteal loca-
ion and the increased loss of collaterals with thrombosis.
The outcome of patients with embolic vs thrombotic
auses of arterial occlusion is of great interest. This could
ot be directly assessed in this study for multiple reasons.
he decreasing prevalence of rheumatic heart disease un-
erlies the diminishing impact of embolic causes for acute
imb ischemia. Only 9% of our cohort had a documented
rrhythmia and in reviewing the original images, only a
andful of cases had clear intraluminal emboli with charac-
eristic angiographic findings. However, in many cases,
mbolus with subsequent proximal and distal thrombosis
ay mimic in situ thrombosis. Thus, for our analyses, we
tratified the patients between native arterial ALI vs graft
hrombosis. We believe a portion of patients with native
rtery thrombosis were from embolic causes.
Kuoppala and colleagues reviewed their experience
ith thrombolysis for lower limb ischemia.16 They com-
iled their outcomes in 220 cases in 195 patients. However,
his included 31 patients with nonacute ischemia. The
verall results were positive with high rates of successful
estoration of blood flow, complete thrombus dissolution,
nd fewmajor complications. During a medial follow-up of
2 months, 57 (26%) amputations were performed. Risk
actors associated with amputations included diabetes, mo-
or deficit on presentation and again, female gender.
In the United Kingdom, a national audit of thrombo-
ytic cases over a 10-year period has been published.18 The
ational Audit of Thrombolysis for Acute Leg Ischemia
NATALI) study compiled results in 1133 thrombolytic
ases, mostly using rt-PA. The overall amputation-free
urvival (AFS) was 75%, with a 12% rate of amputation and
12% rate of death in the first 30 days. Mirroring our
ndings, on multivariable analysis, female gender was asso-
iated with increased risk for mortality (P  .006). Also,
ncreasing age, duration of ischemia, and Fontaine grade
roved to be related to AFS.
The “power-pulse” technique has been used to limit
schemia time by restoring in-line blood flow as soon as
easible. Allie and colleagues have utilized a rheolytic PMT
evice to deliver either urokinase or tenecteplase at high
ressure to lace the thrombus.14 This theoretically allows
etter clot penetration and expedited fibrin degradation.
ed
% CI) P value vs reference P value overall
7) .002 .002
2) .007 .007
6) .67 .013
0) .019
3) .001 .001ariz
o (95
8, 7.0
3, 0.7
5, 1.9
5, 4.8
6, 0.6hen, the PMT device is used to evacuate as much throm-
11
1
1
1
1
1
1
1
1
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February 2011346 Kashyap et albus burden at the initial angiogram. In 49 patients with
ileofemoral thrombosis, mean procedure times were only
73 minutes. Success rates were high and limb salvage at 30
days was 91%. Similarly, Ansel and colleagues described
their experience with PMT in 99 consecutive patients.17 In
a majority of patients (71%), a substantial to complete
amount of the thrombotic occlusion was removed on initial
therapy with only 37% requiring additional thrombolysis.
Multiple studies appear to signal a shift from thrombolysis
only to PMT/thrombolysis to hasten reperfusion with
acceptable early results.20 In our experience, only 20 limbs
underwent the “power pulse” technique while an addi-
tional 38 limbs had PMT used during their endovascular
procedures. We did not show a benefit with PMT in our
analysis. However, it is likely our study suffers from a
selection bias in that the PMT devices were used in more
recent patients with greater clot burden and progressively
worsening ALI symptoms.
Admittedly this study is with several important limita-
tions. First, it represents a retrospective review of database
and medical records without comparable controls. Many of
the patients were from outside institutions transferred to
our tertiary care facility. Thus, our cohort may not repre-
sent the normal ALI population and our results may not be
generalizable. Many of the patients had multiple proce-
dures in the past with variables that may not have been
accounted for. Patients living far away limited follow-up in
some instances, and the planned post-procedure vascular
laboratory testing was not obtained in all patients. Despite
these limitations, we feel this study further validates the role
for endovascular therapy in the treatment of ALI. Although
significant advances have been made in endovascular ther-
apeutic modalities, ALI of the lower extremities still carries
significant morbidity and mortality. Limiting the duration
of thrombolysis and employing increased vigilance in our
female patients may further improve outcomes.
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